The Clinical Psychopharmacology Section conducts preclinical and clinical research into the mechanisms of action of cocaine. A major component of this project, conducted in collaboration with investigators at NIDDK and NIMH, is the synthesis and evaluation of analogs of GBR12909 as putative cocaine antagonists or cocaine substitution-type medications. As part of this project, we synthesized and evaluated the first chiral """"""""GBR"""""""" derivatives as potent and enantioselective inhibitors of dopamine reuptake. In an extension of previous studies, we showed that daily administration of GBR12909 suppresses cocaine self-administration in Rhesus monkeys without the development of tolerance, supporting its potential use in the treatment of cocaine addiction and that GBR12909 blocks the increase in extracellular DA produced by intravenous cocaine. Another component involves investigation of the possible heterogeneity of DA transporter binding sites. This project has identified multiple and novel binding sites for the high affinity cocaine analog, [125I]RTI-55. Another component of this project addresses the role of classical conditioning in cocaine-induced behavioral sensitization. These studies demonstrated that associative learning mechanisms are involved in the acquisition of context-specific behavioral sensitization to cocaine. Studies with genetically inbred strains of mice showed that the occurrence of sensitization is not correlated with either the potency or efficacy of cocaine as a motoric stimulant. Human studies failed to demonstrate cocaine-sensitization with a one day training paradigm (IRP-174). Open-label studies with phentermine and fenfluramine showed that these medications suppress cocaine craving in addicts seeking treatment. Clinical research protocols are in preparation to determine the efficacy of fenfluramine and phentermine as treatments for alcohol and cocaine addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000119-03
Application #
3752852
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Hampson, Robert E; Collins, Vernell; Deadwyler, Sam A (2009) A wireless recording system that utilizes Bluetooth technology to transmit neural activity in freely moving animals. J Neurosci Methods 182:195-204
Hampson, R E; EspaƱa, R A; Rogers, G A et al. (2009) Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology (Berl) 202:355-69
Rothman, Richard B; Baumann, Michael H (2009) Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 8:317-29
Rothman, Richard B; Baumann, Michael H (2009) Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 16:354-64
Opris, I; Hampson, R E; Deadwyler, S A (2009) The encoding of cocaine vs. natural rewards in the striatum of nonhuman primates: categories with different activations. Neuroscience 163:40-54
Rothman, Richard B; Blough, Bruce E; Baumann, Michael H (2008) Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol 16:458-74
Pariser, Joseph J; Partilla, John S; Dersch, Christina M et al. (2008) Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release. J Pharmacol Exp Ther 326:286-95
Gilbert, Kathleen M; Boos, Terrence L; Dersch, Christina M et al. (2007) DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. Bioorg Med Chem 15:1146-59
Rothman, Richard B; Blough, Bruce E; Baumann, Michael H (2007) Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J 9:E1-10
Wang, X; Baumann, M H; Dersch, C M et al. (2007) Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Neuroscience 148:212-20

Showing the most recent 10 out of 59 publications